Summit Global Investments Exelixis, Inc. Transaction History
Summit Global Investments
- $1.57 Billion
- Q3 2024
A detailed history of Summit Global Investments transactions in Exelixis, Inc. stock. As of the latest transaction made, Summit Global Investments holds 25,583 shares of EXEL stock, worth $865,217. This represents 0.04% of its overall portfolio holdings.
Number of Shares
25,583
Previous 34,047
24.86%
Holding current value
$865,217
Previous $765,000
13.2%
% of portfolio
0.04%
Previous 0.05%
Shares
11 transactions
Others Institutions Holding EXEL
# of Institutions
502Shares Held
243MCall Options Held
2.54MPut Options Held
2.29M-
Black Rock Inc. New York, NY33.5MShares$1.13 Billion0.02% of portfolio
-
Vanguard Group Inc Valley Forge, PA29.3MShares$991 Million0.01% of portfolio
-
Farallon Capital Management LLC San Francisco, CA25.4MShares$859 Million3.31% of portfolio
-
Jim Simons Renaissance Technologies LLC | New York, Ny15.4MShares$519 Million0.63% of portfolio
-
State Street Corp Boston, MA11.4MShares$387 Million0.01% of portfolio
About EXELIXIS, INC.
- Ticker EXEL
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 321,832,000
- Market Cap $10.9B
- Description
- Exelixis, Inc., an oncology-focused biotechnology company, focuses on the discovery, development, and commercialization of new medicines to treat cancers in the United States. The company's products include CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ ...